TY - JOUR T1 - EVALUATION OF INTERFERONE-ALPHA TYPE 2a (ROFERON) ON PATIENTS WITH CHRONIC HEPATITIS C TT - بررسی اثر درمانی آلفا اینترفرون نوع 2a (رفرون) روی بیمـاران مبتـلا به هپاتیـت مزمن C JF - RJMS JO - RJMS VL - 10 IS - 33 UR - http://rjms.iums.ac.ir/article-1-139-en.html Y1 - 2003 SP - 61 EP - 71 KW - Key Words: 1) Interferone-alpha 2) Roferon 3) Hepatitis C N2 - Hepatitis C virus infection is affecting an estimated 200 million people worldwide and 210 thousand in Iran. It is a major cause of morbidity and mortality from liver disease. Interferon-alpha is the choice of treatment but interferone (IFN) with ribavirin is known more effective recently. This study evaluated effect of IFN on Iranian patients and predict response to therapy. This is a quasi experimental study on 33 patients of chronic hepatitis C that are treated by IFN-2a, 3 Mega units, three times in week for 12 months, subcutaneously. We assessed ALT, AST, alkaline phosphatase, total and direct billirubine at first, second week and every month till 12 months. HCV-RNA and biopsy were done at first and end of study. T test, chi2, ANOVA, correlation coefficient and regression models were used for analysis. %82.7 were ejucated under diploma. AST, ALT and alkaline phosphatase were decreased under normal range during treatment significantly(P=0.00005, P=0.0005 & P=0.001). Liver enzymes and billirubine normalized 2-4 months after treatment and the first biochemical break through was during first 6 months. %86.7 of all patients response to therapy biochemically. Percent of patients with negative HCV-RNA was more in the end of study significantly. (P M3 ER -